Published in Alzheimers Dement on November 19, 2015
Predicting regional pattern of longitudinal beta-amyloid accumulation by baseline positron emission tomography. J Nucl Med (2016) 0.75
Family History of Alzheimer's Disease is Associated with Impaired Perceptual Discrimination of Novel Objects. J Alzheimers Dis (2017) 0.75
Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimers Dement (Amst) (2016) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
The incidence of dementia: a meta-analysis. Neurology (1998) 3.06
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc (2003) 2.83
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement (2008) 2.52
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology (2012) 2.49
Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement (2011) 2.26
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
The decline of working memory in Alzheimer's disease. A longitudinal study. Brain (1991) 1.91
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology (2013) 1.74
Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. JAMA Neurol (2015) 1.52
Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology (2013) 1.51
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry (2011) 1.34
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement (2014) 1.26
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry (2014) 1.25
Executive decline and dysfunction precedes declines in memory: the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci (2009) 1.24
Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging (2013) 1.14
APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology (2004) 1.10
Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. Clin Neuropsychol (2013) 1.09
Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement (2014) 1.06
Assessment of cognition in mild cognitive impairment: a comparative study. Alzheimers Dement (2011) 1.00
Apolipoprotein E genotype and lifetime cognitive decline. Int Psychogeriatr (2007) 0.95
Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement (2012) 0.88
Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. PLoS One (2013) 0.84
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement (2015) 0.83
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimers Dement (2014) 0.80
Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis (2014) 2.01
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol (2014) 1.89
Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol (2014) 1.56
An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun (2016) 1.45
Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science (2016) 1.43
Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener (2016) 1.41
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement (2015) 1.17
Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement (2013) 1.13
Estimating long-term multivariate progression from short-term data. Alzheimers Dement (2014) 0.99
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol (2016) 0.95
Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging (2014) 0.94
Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. Neurobiol Aging (2014) 0.93
Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging (2014) 0.89
Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement (2016) 0.89
Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiol Aging (2014) 0.87
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst) (2016) 0.86
Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiol Aging (2014) 0.86
Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiol Aging (2014) 0.85
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement (2015) 0.83
Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord (2014) 0.82
Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement (2016) 0.82
Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging (2013) 0.81
Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. Neuroimage (2015) 0.81
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimers Dement (2014) 0.80
Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimers Dement (2016) 0.80
Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther (2016) 0.79
Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging (2014) 0.79
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging (2014) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
Language networks associated with computerized semantic indices. Neuroimage (2014) 0.78
FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. J Alzheimers Dis (2016) 0.78
Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimers Dement (2013) 0.78
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement (2016) 0.78
TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiol Aging (2016) 0.78
Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Med (2016) 0.77
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition. J Alzheimers Dis (2016) 0.77
Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism Relat Disord (2015) 0.77
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. J Alzheimers Dis (2016) 0.77
Alzheimer's disease: The next frontier-Special Report 2017. Alzheimers Dement (2017) 0.76
Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol (2017) 0.76
Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. J Alzheimers Dis (2015) 0.76
Massachusetts Alzheimer's Disease Research Center: Progress and challenges. Alzheimers Dement (2015) 0.76
RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiol Aging (2016) 0.76
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging (2015) 0.76
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging (2017) 0.75
Erratum to: Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener (2016) 0.75
Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. J Alzheimers Dis (2016) 0.75
Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex (2016) 0.75
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst) (2016) 0.75
Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimers Dement (Amst) (2016) 0.75
Life-course blood pressure in relation to brain volumes. Alzheimers Dement (2016) 0.75
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimers Dement (2016) 0.75
Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimers Dement (Amst) (2016) 0.75
A robust biomarker of large-scale network failure in Alzheimer's disease. Alzheimers Dement (Amst) (2017) 0.75
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord (2016) 0.75